Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania.
Akdeniz University School of Medicine, Antalya, Turkey.
Retina. 2019 Jul;39(7):1319-1325. doi: 10.1097/IAE.0000000000002169.
To report outcomes of photodynamic therapy (PDT) as primary treatment for small amelanotic choroidal melanoma.
Retrospective interventional case series of 12 patients with small choroidal melanoma treated with standard-fluence PDT (83 seconds; 50 J/cm) using verteporfin.
Tumor regression, subretinal fluid resolution, best-corrected visual acuity, and PDT complications.
There were 12 eyes with melanoma, demonstrating amelanotic (10 [83%]) or lightly pigmented (n = 2, 17%) appearance. The mean tumor thickness was 2.7 mm (median, 2.8; range 1.8-3.7 mm). After PDT, mean follow-up was 56 months (median, 53; range, 14-91). Outcomes revealed complete tumor regression after 1 session (n = 3, 25%), 2 sessions (n = 3, 25%), and 3 sessions (n = 2, 17%) of PDT, reduced to mean thickness of 2.1 mm (median, 2.0; range 1.2-3.4 mm). Tumors that failed to regress (n = 4, 33%) were further controlled with transpupillary thermotherapy (n = 1) or plaque brachytherapy (n = 3). Subretinal fluid, present in six eyes, demonstrated resolution (n = 5) or progression (n = 1), and one tumor developed new subretinal fluid after PDT (n = 1). Visual outcome was stable (n = 11 eyes) or improved (n = 1). Photodynamic therapy complications included local retina pigment epithelium atrophy at the site of treatment in 3 (25%) eyes, with no effect on macular or optic nerve function.
Primary PDT resulted in complete tumor regression of small amelanotic choroidal melanoma in 67% at mean 5 years, with no major effect on visual acuity.
报告光动力疗法(PDT)作为小无色素性脉络膜黑素瘤的主要治疗方法的结果。
回顾性干预性病例系列研究,12 例小脉络膜黑素瘤患者采用标准强度 PDT(83 秒;50J/cm)联合维替泊芬进行治疗。
肿瘤消退、视网膜下液吸收、最佳矫正视力和 PDT 并发症。
12 只眼患有黑色素瘤,表现为无色素(10 只眼[83%])或轻度色素沉着(n=2,17%)外观。平均肿瘤厚度为 2.7mm(中位数,2.8;范围 1.8-3.7mm)。PDT 后平均随访 56 个月(中位数,53;范围,14-91)。结果显示,1 次 PDT 后完全消退(n=3,25%)、2 次(n=3,25%)和 3 次(n=2,17%)的患者比例分别为 3、3 和 2,肿瘤厚度平均降低至 2.1mm(中位数,2.0;范围 1.2-3.4mm)。未消退的肿瘤(n=4,33%)进一步接受经瞳孔温热疗法(n=1)或眼贴敷放射性治疗(n=3)控制。6 只眼存在视网膜下液,5 只眼吸收,1 只眼进展,1 只眼在 PDT 后出现新的视网膜下液(n=1)。视力稳定(n=11 只眼)或提高(n=1)。PDT 并发症包括 3 只眼(25%)治疗部位局部视网膜色素上皮萎缩,无黄斑或视神经功能影响。
平均 5 年时,小无色素性脉络膜黑素瘤的 PDT 主要治疗结果为 67%的肿瘤完全消退,对视力无明显影响。